AI Article Synopsis
- The mouse monoclonal antibody 25-3, targeting LFA-1 (CD11a), was administered to children undergoing non-identical bone marrow transplants to prevent graft failure.
- Two infusion regimens were tested: one with lower doses (0.1 mg/kg every other day) resulting in low serum antibody levels, and another with higher doses (0.2 mg/kg daily) leading to higher mean serum concentrations.
- The higher daily infusion showed a slightly better engraftment rate, and infusion did not significantly affect leukocyte counts or lead to immunization against the antibody.
Article Abstract
The mouse monoclonal antibody 25-3 specific for the alpha subunit of LFA-1 (CD11a) has been infused to children undergoing HLA non-identical bone marrow transplantation because of lethal inherited diseases or of leukemia in order to prevent graft failure. We have assessed the serum concentrations of the antibody infused according to two regimens: 0.1 mg/kg five times, every alternate day (eight patients) or 0.2 mg/kg daily for 10 days (30 patients). Serum trough levels of 25-3 antibody in the first group were constantly found to be low (less than 0.6 micrograms/ml) while 25-3 serum concentration in the second group rose progressively to a mean value of 2.2 micrograms/ml. Serum antibody concentrations were significantly lower in patients with greater antigenic mass, i.e. with splenomegaly, or non conditioned. The engraftment rate was slightly higher in patients treated by the daily infusion of 25-3 for 10 days. No immunization against 25-3 antibody occurred. One patient who subsequently received other mouse anti-B cell antibodies eventually produced anti-isotype antibodies. The consequences of 25-3 infusion on leukocyte counts has been evaluated in the group of patients (n = 6) with severe combined immunodeficiency who did not receive any chemotherapy and in one who was treated with 25-3 because of acute graft-versus-host disease. In none of the cases did 25-3 antibody infusion modify blood leukocyte counts. In addition, it was shown that saturation of LFA-1 on leukocytes was a transient phenomenon, since it could not be found 24 h following infusion of 25-3 antibody.(ABSTRACT TRUNCATED AT 250 WORDS)
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Strategy to mitigate aggregation during Protein A chromatography and low pH virus inactivation for a nivolumab biosimilar candidate.
J Chromatogr A
January 2025
Center of Molecular Immunology, 216 Street and 15th Avenue Atabey-Siboney Playa P.O. Box 16040, Havana, 11600, Cuba. Electronic address:
Protein A chromatography represents the most prevalent methodology for the capture of monoclonal antibodies. The use of a low pH elution buffer from Protein A has been observed to contribute to product aggregation, particularly in the case of IgG4 antibodies, such as nivolumab. This paper presents a well-defined strategy for addressing this issue.
View Article and Find Full Text PDFHepatitis E virus (HEV) infection among the Arab population in Northern Israel: an insight into the seroepidemiology and associated risk factors.
Epidemiol Infect
January 2025
Gastroenterology Department, Nazareth Hospital EMMS, Azrieli Faculty of Medicine, Bar Ilan University, Ramat-Gan, Israel.
Hepatitis E virus (HEV) is one of the most common causes of viral hepatitis. We examined HEV seroprevalence and associations of sociodemographic and lifestyle characteristics with HEV immunoglobulin G (IgG) seropositivity in the Arab population. A cross-sectional single-centre study was conducted among adults in the Nazareth area during 2022.
View Article and Find Full Text PDFFuture atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes.
BMC Med
January 2025
Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No. 1 Shuaifuyuan, Wangfujing Ave, Beijing, 100730, China.
Background: Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases. In this multi-center prospective study, we aimed to determine the association between antiphospholipid antibodies (aPLs) and future atherosclerotic cardiovascular disease (ASCVD) in SLE.
Methods: In total, 1573 SLE patients were recruited based on the Chinese SLE Treatment and Research group (CSTAR) registry.
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.
J Immunother Cancer
November 2024
Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China.
Article Synopsis
- A phase 3 study showed that combining camrelizumab with chemotherapy significantly improved progression-free survival in patients with advanced non-squamous non-small-cell lung cancer compared to chemotherapy alone.
- After 5 years, overall survival rates were 31.2% for those receiving camrelizumab and chemotherapy versus 19.3% for those on chemotherapy alone, indicating a substantial benefit.
- Patients who completed two years of treatment with camrelizumab had an impressive 5-year overall survival rate of 84.3%, reinforcing its effectiveness and safety as a first-line therapy for this cancer type.
Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis.
J Comp Eff Res
December 2024
Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC 28207, USA.
Article Synopsis
- In rheumatoid arthritis, having both anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF) indicates more severe disease and can affect treatment outcomes; abatacept is a recommended biologic treatment for those who don't respond to traditional medications.
- A study tracking 296 RA patients treated with abatacept showed significant improvement in clinical disease activity over 12 months, with mean disease activity scores decreasing by up to 74% after treatment.
- Among patients who initially had high disease activity, about 71% achieved low disease activity or remission during the follow-up, and serious adverse events were reported in only 2.4% of cases, highlighting abatacept's effectiveness and safety.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!